We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

84 hedge funds and large institutions have $106M invested in Syndax Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

35% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 20

17% more funds holding

Funds holding: 72 → 84 (+12)

8.48% less ownership

Funds ownership: 69.53% → 61.05% (-8.5%)

14% less call options, than puts

Call options by funds: $387K | Put options by funds: $448K

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less capital invested

Capital invested by funds: $244M → $106M (-$138M)

Holders
84
Holders Change
+12
Holders Change %
+16.67%
% of All Funds
1.92%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
22
Increased
27
Reduced
20
Closed
10
Calls
$387K
Puts
$448K
Net Calls
-$61K
Net Calls Change
-$299K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.87M
2
SCM
Stonepine Capital Management
Oregon
+$1.95M
3
Macquarie Group
Macquarie Group
Australia
+$1.77M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.58M
5
6CM
683 Capital Management
New York
+$900K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$19.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.27M
3
SFM
Sphera Funds Management
Israel
-$4.25M
4
OM
Opaleye Management
Massachusetts
-$3.17M
5
ACM
Asymmetry Capital Management
California
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$527K +$576K +58,706 +358%
AG
27
Algert Global
California
$516K +$721K +73,499 New
Los Angeles Capital Management
28
Los Angeles Capital Management
California
$492K +$559K +56,988 +433%
AG
29
Artal Group
Luxembourg
$426K -$876K -89,303 -60%
Aviva
30
Aviva
United Kingdom
$423K +$592K +60,318 New
MCIM
31
Meadow Creek Investment Management
Georgia
$406K +$28.4K +2,890 +5%
GCP
32
GSA Capital Partners
United Kingdom
$368K +$514K +52,400 New
BCM
33
Bridgeway Capital Management
Texas
$355K – – –
OAM
34
Oxford Asset Management
United Kingdom
$349K -$709K -72,235 -59%
TI
35
Telemetry Investments
New York
$344K +$481K +49,000 New
EP
36
Elkfork Partners
Oregon
$335K +$23.4K +2,380 +5%
Renaissance Technologies
37
Renaissance Technologies
New York
$297K -$100K -10,200 -19%
Jacobs Levy Equity Management
38
Jacobs Levy Equity Management
New Jersey
$287K +$400K +40,815 New
GHCM
39
Glen Harbor Capital Management
California
$263K +$18.3K +1,870 +5%
Deutsche Bank
40
Deutsche Bank
Germany
$262K -$71.3K -7,264 -16%
AA
41
ALPS Advisors
Colorado
$252K +$30.8K +3,139 +10%
CM
42
Crestline Management
Texas
$246K -$16.6K -1,687 -5%
TCIM
43
TIAA CREF Investment Management
New York
$209K -$669K -68,230 -70%
SIM
44
Spark Investment Management
New York
$198K +$278K +28,300 New
Bank of America
45
Bank of America
North Carolina
$197K +$257K +26,189 +1,382%
NA
46
Neuburgh Advisers
California
$191K +$13.3K +1,360 +5%
TA
47
Teachers Advisors
New York
$179K – – –
Charles Schwab
48
Charles Schwab
California
$172K – – –
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$159K +$44.1K +4,491 +25%
Citadel Advisors
50
Citadel Advisors
Florida
$158K +$221K +22,498 New
1
2
3 4

SNDX Hedge Fund Activity: Q2 2018 in Review

84 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2018, worth a combined $106M — down 57% from $244M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new SNDX positions and 10 closed out — a net gain of 12 holders — while 27 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $3.87M. The largest seller was BVF Inc, cutting an estimated $19.6M.

  • 84 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2018, up from 72 in Q1 2018.
  • Funds reported $106M of Syndax Pharmaceuticals stock for Q2 2018, down 57% quarter-over-quarter.
  • 22 funds opened new Syndax Pharmaceuticals positions in Q2 2018 and 10 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $3.87M added.
  • The largest Syndax Pharmaceuticals seller in Q2 2018 was BVF Inc, an estimated $19.6M sold.

Based on aggregated 13F filings for Q2 2018.